Sermorelin and Tesamorelin are supplied strictly as laboratory research materials. They are not approved, intended or authorised for human consumption or any therapeutic use in this context. This article is written for qualified researchers and is not medical advice.
Two takes on the same receptor
Sermorelin and Tesamorelin are both GHRH analogues: each binds the growth-hormone-releasing hormone receptor (GHRH-R) on pituitary somatotrophs and drives the gland to secrete its own growth hormone, rather than delivering exogenous GH from outside. That shared mechanism means both preserve the physiological machinery that recombinant GH bypasses — pulsatile release, somatostatin feedback, and an intact GH/IGF-1 axis. Where they diverge is in how the molecule is built, and therefore how long it survives in circulation and how potent a stimulus it delivers. Below, the two compounds sit side by side before we take each in turn.
| Sermorelin | Tesamorelin | |
|---|---|---|
| Class / peptide type | GHRH analogue — GRF(1-29), the shortest fully active fragment | Stabilised GHRH analogue — full-length, DPP-4-resistant |
| Primary target | GHRH-R on pituitary somatotrophs (cAMP → GH secretion) | GHRH-R on pituitary somatotrophs (endogenous, pulsatile GH) |
| Structure / MW | 29 amino acids (GHRH residues 1–29) | 44 amino acids, N-terminal trans-3-hexenoyl; ~5135.86 Da |
| Half-life / duration | ~11 minutes (brief) | ~25–40 minutes (substantially longer) |
| Main research focus | GH-axis reference compound; longevity / ageing biology | Visceral adiposity; lipodystrophy; IGF-1 axis |
| Regulatory status | Former FDA approval (paediatric), commercially withdrawn | FDA-approved as Egrifta (2010) for HIV lipodystrophy |
Sermorelin: the classic short fragment
Sermorelin — also written GRF(1-29) or GHRH(1-29) — is a 29-amino-acid synthetic analogue of the first 29 residues of native GHRH, and represents the shortest fragment that still carries the hormone's full biological activity. It binds GHRH-R on somatotrophs, activates the cAMP/PKA cascade, and stimulates endogenous GH gene transcription. Its defining research feature is preservation of the hypothalamic-pituitary negative feedback loop: because it prompts the pituitary to make its own GH, somatostatin can still regulate the output, the release stays pulsatile, and the system cannot easily be overdriven the way constant-infusion exogenous GH can.
The cost of that clean, physiological profile is duration. Sermorelin's half-life is only around 11 minutes, which is why the historical literature leans on frequent dosing or modified delivery, and why the field turned toward longer-acting GHRH analogues in the first place. It was previously FDA-approved for paediatric growth disorders before being commercially withdrawn, and it has since served mainly as a well-characterised reference compound in GH-axis and ageing-biology research. Researchers sourcing material can buy Sermorelin UK in research grade, and the full pharmacology sits on our Sermorelin knowledgebase page.
Tesamorelin: the stabilised, longer-acting analogue
Tesamorelin (TH9507, marketed as Egrifta) takes the opposite tack. Rather than trimming GHRH down, it keeps the full 44-residue sequence and adds an N-terminal trans-3-hexenoyl group. That modification is the whole point: native GHRH is cleaved by dipeptidyl peptidase-4 (DPP-4) within minutes, but the modified backbone resists that cleavage, extending receptor activation. The result is a half-life in the region of 25–40 minutes and, compared with sermorelin's short 1-29 fragment, a markedly more potent and longer-lasting stimulus to endogenous GH release — while still working through the same somatotroph GHRH receptor and preserving pulsatile, feedback-regulated output.
Its research identity is also more specific. Tesamorelin is the only GHRH analogue to have earned FDA approval as a medicinal product — cleared in 2010 for HIV-associated lipodystrophy — and the clinical programme documented preferential reduction of visceral adipose tissue with parallel improvements in lipid and insulin-resistance markers, alongside IGF-1 rises that stayed near the top of the normal range. That gives it the deepest evidence base of any compound in the class and anchors it to visceral-fat and metabolic research. In stack work it is often paired with the selective GHRP ipamorelin, which engages a parallel receptor. Material is available to buy Tesamorelin UK, with the mechanism detailed on the Tesamorelin knowledgebase page.
What the differences mean in a research context
Read the table top to bottom and the contrast is structural, not conceptual. Both molecules pull the same lever — GHRH-R on the pituitary — so the qualitative behaviour (endogenous, pulsatile, feedback-preserving GH release) is shared. What separates them is engineering: sermorelin is the minimal active fragment, prized for a clean, well-understood profile but hobbled by an ~11-minute half-life; tesamorelin is the stabilised full-length molecule, trading fragment simplicity for DPP-4 resistance, greater potency and a duration several times longer.
That difference steers the research questions each is suited to. Sermorelin's role is as a reference point — the baseline GHRH analogue against which stabilised successors are measured, and a natural tool where preserving the most physiological release pattern matters more than potency or convenience. Tesamorelin's longer action and its specific, approved lipodystrophy evidence make it the choice where the experimental aim is a sustained GH stimulus or where visceral-fat and IGF-1 endpoints are in view. Neither is "better" in the abstract; they answer different questions, and the two are often studied precisely to isolate what the DPP-4-stabilising modification and the extra residues actually buy.
One caveat researchers should hold onto: the two carry different depths of data. Tesamorelin's profile rests on a mature Phase 3 clinical dataset behind its approval, whereas much of sermorelin's characterisation comes from its earlier, now-withdrawn approval and subsequent reference use. All figures cited here derive from published literature on the regulated products — the material RS Bio Labs supplies is a laboratory reagent for in vitro work only.
The bottom line
Sermorelin and Tesamorelin are the same idea executed two ways: stimulate the pituitary's own GH output through GHRH-R while keeping the physiological feedback intact. Sermorelin is the classic short GRF(1-29) fragment — clean, well-characterised, but brief. Tesamorelin is the stabilised, full-length analogue — more potent, longer-acting, and backed by the deepest clinical evidence in the class. For research-grade material, see our dedicated pages to buy Sermorelin UK and buy Tesamorelin UK, each ≥99% purity with a COA.